<DOC>
	<DOC>NCT00990301</DOC>
	<brief_summary>The purpose of this study was to evaluate the relative bioavailability of Paddock Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets with a reference formulation UnireticÂ®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets, under fasting conditions.</brief_summary>
	<brief_title>A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Moexipril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening Positive test results for HIV or Hepatitis B or C History of allergy or sensitivity to Moexipril, Hydrochlorothiazide or related drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>